ArticleHepatobiliary surgery and nutrition2023
Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
Article in Hepatobiliary surgery and nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Pooled it
- Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.Frontiers in oncology · 2024Pooled it
- Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies.Frontiers in oncology · 2024Pooled it
- Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes.Hepatology international · 2023Pooled it
- Article
- Influence of MASLD and MAFLD on long-term extrahepatic cancer incidence and cancer mortality in regional Australia.Internal medicine journal · 2026Article
- Hypertension Associated with the Risk of Extrahepatic Cancers in the Metabolic Dysfunction-associated Steatotic Liver Disease Population: A Multicenter Cross-sectional Study in China.Journal of clinical and translational hepatology · 2026Article
- Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999-2018 and an exploratory hospital-based dataset.Frontiers in oncology · 2026Article
- Prevalence and impact of metabolic associated fatty liver disease in non-metastatic breast cancer women at initial diagnosis: a cross-sectional study in China.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025.Clinical and molecular hepatology · 2025Article
- Association between surrogate indices of fatty liver and the risk of colorectal cancer: a cross-sectional United States study.Translational cancer research · 2025Article
- Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study.BMC gastroenterology · 2025Article
- Overweight andFrontiers in cellular and infection microbiology · 2025Article
- ASSOCIATION BETWEEN OBESITY AND BRAFV600E MUTATION IN PAPILLARY THYROID CARCINOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the associations between a new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) and extrahepatic cancers and compare with nonalcoholic fatty liver disease (NAFLD). Methods: We enrolled 151,391 Chinese participants in the Kailuan cohort. Hepatic steatosis was detected by abdominal ultrasound. Fine and Gray competing risk regression models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI) between MAFLD and extrahepatic cancers. Results: MAFLD was associated with increased risk of prostate (HR =1.49, 95% CI: 1.07-2.08) and obesity-related cancers, including thyroid (HR =1.47, 95% CI: 1.01-2.12), kidney (HR =1.54, 95% CI: 1.18-2.00), colorectal (HR =1.15, 95% CI: 0.98-1.34) and breast cancer (HR =1.31, 95% CI: 1.04-1.66). The results were consistent in NAFLD Conclusions: MAFLD and NAFLD shared similar excessive risks of obesity-related cancers, suggesting a driving role of FLD in these cancers. Metabolic dysregulation beyond obesity may play additional kidney, colorectal, and prostate cancer risks in MAFLD patients. It may be helpful in the clinic to relieve symptoms by treating metabolic disorders and preventing adverse outcomes of extrahepatic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.